Shang­hai Jun­shi Bio­sciences next to test HKEX list­ing; With one eye on Sage, Mar­i­nus re­ports pre­lim PPD da­ta

→ The new rule al­low­ing biotechs to list on the Hong Kong ex­change be­fore record­ing rev­enue or prof­it has at­tract­ed a mixed bag of per­form­ers, in­clud­ing As­cle­tis, BeiGene, and In­novent Bi­o­log­ics. The lat­est com­pa­ny will­ing to wa­ger its for­tunes is Shang­hai Jun­shi Bio­sciences (with its 13 bi­o­log­ics in de­vel­op­ment), which is seek­ing up to $414 mil­lion in a bid to go pub­lic on HKEX, ac­cord­ing to a Reuters re­port.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER